Professional
Added to YB: 2026-07-02
Pitch date: 2026-05-21
ZBIO [neutral]
Zenas BioPharma, Inc.
+40.07%
current return
Author Info
No bio for this author
Company Info
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.
Market Cap
$1.6B
Pitch Price
$19.99
Price Target
N/A
Dividend
N/A
EV/EBITDA
-4.64
P/E
-2.90
EV/Sales
N/A
Sector
Biotechnology
Category
N/A
Meridian Contrarian Fund Portfolio Holding: Zenas BioPharma, Inc.
ZBIO (holding update): Clinical-stage biopharma in autoimmune/inflammatory diseases; invested 2022 amid tough biotech funding. Q1 2026 detractor as lead fibroinflammatory drug trial missed efficacy vs peers, but fund sees efficacy adequate for commercialization + superior safety, delivery & cost. Maintains modest position.
Read full article (1 min)